All In Biotech

Drug Trial Radar · NCT04471922

A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

A Single-center, Randomized, Double-blinded, Placebo and Active Controlled Phase 1 Study to Evaluate the Safety and Pharmacology of Multiple Ascending Dose Administration of Anaprazole in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Jul 15, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Mar 21, 2019

Primary completion

Mar 28, 2019

Study completion Mar 28, 2019

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single-center, randomized, double-blinded, placebo parallel controlled phase 1 study to evaluate the safety and pharmacokinetics/pharmacodynamics of multiple (7 days) ascending dose (60mg QD, 80mg QD, 100mg Qd) administrationof Anaprazole in healthy Chinese subjects. 45 subjects, 15 subjects for each dose group. In each dose group, 10 subjects take investigational drug (anaprazole), 2 subjects take active comparatory drug (rabeprazole), 3 subjects take placebo.

Conditions

  • Healthy Volunteers

Interventions

  • Anaprazole Sodium enteric-coated tabletDrug

    Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.

  • PlaceboDrug

    Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.

  • Active controlled (rabeprazole)Drug

    Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0Time frame: From signing informed consent to study completion at 14 days after fist dose administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.